NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer

20 Apr 2021 03:45 PM

NICE yesterday (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.